The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Schnitzler Syndrome

Rare autoinflammatory disease characterized by chronic urticaria, monoclonal IgM gammopathy and systemic inflammation.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Schnitzler Syndrome?

Schnitzler syndrome is a rare adult-onset autoinflammatory disease first described in 1972 by Liliane Schnitzler; fewer than 300 cases reported worldwide.

Epidemiology: typical age at onset 51–55 years, slight male predominance (3:2), no clear ethnic predilection; chronic course over decades.

Pathophysiology: dysregulated IL-1β production by myeloid cells, NLRP3 inflammasome activation, neutrophilic urticarial dermatosis on histology; underlying mechanism distinct from classical mast cell-mediated urticaria.

Strasbourg diagnostic criteria: chronic urticarial rash and monoclonal IgM gammopathy plus 2 of: recurrent fever, abnormal bone remodeling, neutrophilic infiltrate on skin biopsy, leukocytosis or elevated CRP.

Symptoms

Chronic recurrent urticarial rash (95–100%): non-pruritic or mildly pruritic flat erythematous plaques, predominantly trunk and extremities, lasting 12–24 hours, daily or near-daily occurrence
Recurrent low-grade to high-grade fever (90%): typically 1–2 episodes per week, no clear infectious trigger
Bone pain (80%): deep aching pain in pelvis, hips, lumbar spine and lower extremities; abnormal bone remodeling on imaging
Arthralgia and arthritis (60%): non-erosive, large joint involvement
Lymphadenopathy and hepatosplenomegaly (30–45%)
Constitutional symptoms: fatigue, weight loss, night sweats
Anemia of chronic disease (50%)
Risk of progression to lymphoplasmacytic malignancy (Waldenström macroglobulinemia, multiple myeloma): 15–20% over 10–15 years
Severe AA amyloidosis as a long-term complication (rare)

Risk Factors

Adult onset, typically age 50–60 years
Slight male predominance (1.5:1)
No identified genetic mutations (sporadic disease)
No environmental or infectious trigger established
Family history negative; not familial
Underlying monoclonal gammopathy of undetermined significance (MGUS) IgM type
Lymphoplasmacytic disorder evolution risk over decades
Coexisting MGUS-related conditions: peripheral neuropathy, hyperviscosity

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Recurrent or chronic urticarial rash unresponsive to antihistamines
  • Recurrent fevers without identifiable infectious cause
  • Persistent bone pain, especially with abnormal bone-remodeling imaging
  • Elevated CRP/ESR with normal blood cultures and viral serologies
  • Newly diagnosed monoclonal IgM gammopathy with systemic symptoms
  • Suspected autoinflammatory disease in adult patients
  • Worsening symptoms or new neurological complaints (peripheral neuropathy)
  • Symptoms of systemic disease: lymphadenopathy, splenomegaly, anemia

Treatment Methods

01
Diagnostic workup: serum protein electrophoresis with immunofixation, free light chains, IgM quantitation; complete blood count with differential, ESR, CRP, ferritin, fibrinogen
02
Bone imaging: plain radiography of pelvis, long bones; bone scan/MRI demonstrating osteosclerosis, hyperostosis or focal bone abnormalities
03
Skin biopsy: neutrophilic urticarial dermatosis with leukocytoclastic infiltrate without true vasculitis or vasculopathy; characteristic histology distinguishes from classical urticaria
04
Bone marrow biopsy: assessment for lymphoplasmacytic infiltrate, exclusion of evolving lymphoma or myeloma
05
Excluded conditions: cold autoinflammatory syndromes (CAPS), adult-onset Still disease, hyper-IgD syndrome, lymphoma, multiple myeloma, urticarial vasculitis
06
First-line therapy: anakinra (IL-1 receptor antagonist) 100 mg subcutaneously daily; dramatic and rapid response within hours, complete remission in >90%
07
Canakinumab (anti-IL-1β monoclonal antibody): 150–300 mg subcutaneously every 8 weeks; long half-life enables monthly to two-monthly dosing; alternative to anakinra
08
Rilonacept (IL-1 trap): 160–320 mg subcutaneously weekly; less commonly used but effective alternative
09
Antihistamines (H1 and H2 blockers): minimally effective and not recommended as monotherapy
10
Systemic corticosteroids (prednisolone 30–60 mg/day): partial response; long-term use limited by adverse effects; reserved for transition or refractory disease
11
NSAIDs (indomethacin, naproxen): may relieve symptoms but only partial response
12
Colchicine, dapsone, methotrexate, hydroxychloroquine: variable and limited response; secondary options
13
Rituximab: case reports of response in IgM-associated disease; reserved for refractory or progression to lymphoplasmacytic malignancy
14
Monitoring during IL-1 blockade: complete blood count, infection screening (TB, hepatitis B/C), monthly clinical assessment, IgM levels every 3–6 months
15
Long-term surveillance: serial monoclonal protein measurement, bone marrow biopsy if rising IgM or new symptoms; surveillance for progression to Waldenström macroglobulinemia
16
Vaccination: pneumococcal, influenza and herpes zoster vaccines prior to biologic therapy; no live vaccines on therapy
17
Quality-of-life management: pain management, sleep optimization, psychological support, patient education on chronic course
18
Prognosis with anakinra/canakinumab: excellent symptomatic control with sustained remission for years; underlying gammopathy progression independent of inflammation control
19
Multidisciplinary follow-up: rheumatology, hematology and dermatology; lifelong monitoring required

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.